Comparing Results with Futibatinib and Pemigatinib versus Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusion or Other Rearrangements

March 2022, Vol 3, No 1

The phase 2 FOENIX-CCA2 clinical trial evaluated the investigational FGFR1-4 inhibitor futibatinib in patients with advanced intrahepatic cholangiocarcinoma (CCA) harboring FGFR2 fusion or other rearrangements.

In the absence of head-to-head clinical trials comparing the currently available FGFR inhibitors, Mitesh J. Borad, MD, Mayo Clinic, Phoenix, AZ, and colleagues conducted an indirect treatment comparison of efficacy outcomes that have been previously published with futibatinib therapy from the FOENIX-CCA2 study versus outcomes with chemotherapy plus FGFR inhibitors. Dr Borad presented the results at the 2022 ASCO GI Cancers Symposium.

This systematic literature review identified clinical trials with FGFR inhibitors that were published between January 2015 and February 2021, and used additional targeted searches for chemotherapy data. Dr Borad and colleagues used the population-adjusted simulated treatment comparison method, and applied individual-level patient data from FOENIX-CCA2 as well as published aggregate data from comparator clinical trials, adjusting for between-study differences in baseline characteristics.

Population-adjusted Cox regression models were used for base-case time-to-event outcomes, including progression-free survival (PFS), overall survival (OS), duration of response (DOR), and binomial-logistic regressions for binary outcomes, namely, objective response rate (ORR).

Two studies were identified for FGFR inhibitors in previously treated patients with FGFR2 fusion or other rearrangements—FOENIX-CCA2 for futibatinib (N = 103) and FIGHT-202 for pemigatinib (N = 107). For chemotherapy in this setting, 2 studies were identified—an analysis of previous systemic therapy in the FIGHT-202 cohort (N = 53), and a natural history study using a clinico-genomic database (N = 71).

In the base-case analysis of futibatinib versus chemotherapy, the patients who received futibatinib had a significantly longer PFS compared with chemotherapy (hazard ratio [HR], 0.53) and OS (HR, 0.49). In the base-case comparisons of futibatinib versus pemigatinib, treatment with futibatinib was associated with a numerical advantage for all the efficacy parameters, including PFS (HR, 0.89), OS (HR, 0.83), DOR (HR, 0.75), and ORR (HR, 1.43); however, these outcomes did not reach statistical significance.

These data show that futibatinib provides survival advantage compared with chemotherapy in previously treated patients with advanced intrahepatic CCA harboring FGFR2 fusion or other rearrangements. In addition, although significant differences in efficacy outcomes were not found between futibatinib and pemigatinib, the numerical trends favored futibatinib over pemigatinib in patients with intrahepatic CCA, Dr Borad noted.

Source

Borad MJ, Paine A, Wacheck V, et al. Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements. Abstract 440.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC
March 2023, Vol 4, No 1
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: